183 related articles for article (PubMed ID: 32620205)
1. [Oligorecurrent prostate cancer: current management and perspectives].
Loubersac T; Guimas V; Rio E; Libois V; Rigaud J; Supiot S
Bull Cancer; 2020 Jun; 107(5S):S35-S40. PubMed ID: 32620205
[TBL] [Abstract][Full Text] [Related]
2. PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
De Bruycker A; Spiessens A; Dirix P; Koutsouvelis N; Semac I; Liefhooghe N; Gomez-Iturriaga A; Everaerts W; Otte F; Papachristofilou A; Scorsetti M; Shelan M; Siva S; Ameye F; Guckenberger M; Heikkilä R; Putora PM; Zapatero A; Conde-Moreno A; Couñago F; Vanhoutte F; Goetghebeur E; Reynders D; Zilli T; Ost P
BMC Cancer; 2020 May; 20(1):406. PubMed ID: 32398040
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Metastasis-directed Therapy (SBRT) Guided by PET-CT
Mazzola R; Francolini G; Triggiani L; Napoli G; Cuccia F; Nicosia L; Livi L; Magrini SM; Salgarello M; Alongi F
Clin Genitourin Cancer; 2021 Jun; 19(3):230-236. PubMed ID: 32863189
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Hormone-Sensitive Oligorecurrent Prostate Cancer Patients Based on Routine Use of Choline and/or PSMA PET/CT to Guide Metastasis-Directed Therapy.
Metz R; Rauscher A; Vaugier L; Supiot S; Drouet F; Campion L; Rousseau C
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980784
[TBL] [Abstract][Full Text] [Related]
6. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
Glicksman RM; Metser U; Vines D; Valliant J; Liu Z; Chung PW; Bristow RG; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Green D; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
Eur Urol; 2021 Sep; 80(3):374-382. PubMed ID: 33685838
[TBL] [Abstract][Full Text] [Related]
7. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
[TBL] [Abstract][Full Text] [Related]
9. OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.
Supiot S; Vaugier L; Pasquier D; Buthaud X; Magné N; Peiffert D; Sargos P; Crehange G; Pommier P; Loos G; Hasbini A; Latorzeff I; Silva M; Denis F; Lagrange JL; Morvan C; Campion L; Blanc-Lapierre A
Eur Urol; 2021 Oct; 80(4):405-414. PubMed ID: 34247896
[TBL] [Abstract][Full Text] [Related]
10. Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancer.
Fodor A; Lancia A; Ceci F; Picchio M; Hoyer M; Jereczek-Fossa BA; Ost P; Castellucci P; Incerti E; Di Muzio N; Ingrosso G
World J Urol; 2019 Dec; 37(12):2607-2613. PubMed ID: 29752513
[TBL] [Abstract][Full Text] [Related]
11. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation therapy in patients with metachronous oligorecurrent prostate cancer: A single-center experience.
de Pablos-Rodríguez P; la Rosa A; Rebez G; Mascarós Martínez JM; González Pérez V; Arribas Alpuente L; Rubio-Briones J; Ramírez-Backhaus M
Actas Urol Esp (Engl Ed); 2022 May; 46(4):238-244. PubMed ID: 35321821
[TBL] [Abstract][Full Text] [Related]
13. SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
Rans K; Charlien B; Filip A; Olivier H; Julie DH; Céderic D; Herlinde D; Benedikt E; Karolien G; Annouschka L; Nick L; Kenneth P; Carl S; Koen S; Hans V; Ben V; Steven J; Gert M
BMC Cancer; 2022 Dec; 22(1):1294. PubMed ID: 36503429
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
15. Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.
Decaestecker K; De Meerleer G; Ameye F; Fonteyne V; Lambert B; Joniau S; Delrue L; Billiet I; Duthoy W; Junius S; Huysse W; Lumen N; Ost P
BMC Cancer; 2014 Sep; 14():671. PubMed ID: 25223986
[TBL] [Abstract][Full Text] [Related]
16. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.
Ost P; Siva S; Brabrand S; Dirix P; Liefhooghe N; Otte FX; Gomez-Iturriaga A; Everaerts W; Shelan M; Conde-Moreno A; López Campos F; Papachristofilou A; Guckenberger M; Scorsetti M; Zapatero A; Villafranca Iturre AE; Eito C; Couñago F; Muto P; Van De Voorde L; Mach N; Bultijnck R; Fonteyne V; Moon D; Thon K; Mercier C; Achard V; Stellamans K; Goetghebeur E; Reynders D; Zilli T
Eur Urol Oncol; 2024 Jun; 7(3):462-468. PubMed ID: 37821242
[TBL] [Abstract][Full Text] [Related]
17. PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment.
Bianchi L; Ceci F; Balestrazzi E; Costa F; Droghetti M; Piazza P; Pissavini A; Presutti M; Farolfi A; Mei R; Castellucci P; Gandaglia G; Larcher A; Robesti D; Mottrie A; Briganti A; Morganti AG; Fanti S; Montorsi F; Schiavina R; Brunocilla E
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046687
[TBL] [Abstract][Full Text] [Related]
18. Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT.
Gomez-Iturriaga A; Casquero Ocio F; Ost P; Fernandez I; Rodeño E; Llarena R; Garcia-Olaverri J; Ortiz de Zarate R; Cacicedo J; Ahtamon A; Bilbao P
Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13093. PubMed ID: 31115124
[TBL] [Abstract][Full Text] [Related]
19. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer.
De Bleser E; Tran PT; Ost P
Curr Opin Urol; 2017 Nov; 27(6):587-595. PubMed ID: 28816714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]